EATRIS annual report 2018 is available

EATRIS is happy to present the Annual Report for 2018, the fifth year of active operations for EATRIS ERIC. You will learn about the year’s highlights and notable milestones, presented in a more personal format, told by the passionate advocates of Translational Medicine in EATRIS.


11.7 teslas: The World-Record Magnetic Field Generated by a Human MRI Magnet

The Iseult project magnet being installed at Neurospin (CEA Paris-Saclay) reached a nominal magnetic field of 11.7 teslas (T) on July 18, 2019. This is a world record for a whole-body magnetic resonance imager (MRI) magnet, the culmination of years of R&D and at the forefront of innovation in the field of superconducting magnets. Over the coming months, the equipment required for neuroimaging will be installed around the magnet and in its central tube to create a human MRI scanner capable of examining the brain more accurately than ever before, in the interest of fundamental research, cognitive sciences and diagnosing neurodegenerative diseases.

Find out more here:

SAVE THE DATE: HOPE 2020, January 29-31, Paris

The second edition of the "pHysiopathology of Parkinson's DisEase" (HOPE) conference, co-organized by NeurATRIS, will be held from 29 to 31 January 2020 at ICM in Paris.

Following the success of the first edition and the very stimulating feedback from participants regarding the latest scientific advances and the integration of basic research into clinical research, we are pleased to invite you to take part in this second edition.

The topics will cover the epigenetic and genetic determinants of Parkinson's disease, their molecular mechanisms and their modelling, in order to better understand the pathophysiology of Parkinson's disease and open pre-clinical, clinical and imaging perspectives.

In addition we propose a workshop the first day on two topics that will be discussed later on during the congress

1)      Cellular modelling using microfluidic and stem cell technologies

2)      Available imaging tools for cellular models and to humans

The definitive program and registrations will soon be available on the conference website:

A new target to treat spinocerebellar ataxia ?

Spinocerebellar ataxias are genetic neurodegenerative diseases of the cerebellum and brainstem causing numerous motor disorders, for which no curative or preventive therapies are available. SCA3 or Machado-Joseph disease (MJD) is the most prevalent ataxia worldwide. In their work published on June 14 in Acta Neuropathologica, Nathalie Cartier-Lacave, researcher from Inserm at the Brain and Spine Institute and NeurATRIS member, and her team have discovered the crucial role of an enzyme allowing to alleviate symptoms of the disease in mice.

Read the complete press release on the ICM website (in French):

Scientific Publication:


Nóbrega C, Mendonça L, Marcelo A, Lamazière A, Tomé S, Despres G, Matos CA, Mechmet F, Langui D, den Dunnen W, de Almeida LP, Cartier N, Alves S.

Acta Neuropathol. 2019 Jun 14.